This isn’t CNS Pharma’s most recent raise. Rule 506(b) · Equity · May 2026 (Open) is more current.View latest round

Reg A+ · Equity · Jun 2018

WithdrawnReg A+Equity

via Boustead Securities LLC · last checked Sep 24, 2026

Raised

$0 / $17.3M max

0% of ceiling

Investors

—

Valuation

—

Financials disclosed in this offering

No financial statements linked to this round

The issuer's filing for this offering hasn't been parsed into fiscal-year statements yet.

Amendments to this offering

3 amendments

Oct 26, 2018
Terms not yet extracted from this filing
Form 1-A/A on EDGAR ↗
Oct 12, 2018
Terms not yet extracted from this filing
Form 1-A/A on EDGAR ↗
Sep 10, 2018
Terms not yet extracted from this filing
Form 1-A/A on EDGAR ↗

Each line compares the amendment with the previous filing of this offering. Form 1-A amendments state no reason; those filed before qualification are usually responses to SEC staff review.

Deal terms

Price / share$6.00

Shares offered2,875,000

Offering details

Target—

Max$17,250,000

Min investment—

OpenedJun 15, 2018

Deadline—

ClosedMar 28, 2019

Days active286

Links & provenance

SEC filing

Source: SEC EDGAR
0001683168-18-001713
Last synced Sep 24, 2026

About this data. Raised amounts and investor counts come from the platform listing and may lag or be restated; SEC-reported totals can differ until the next Form 1-Z/C-U. Post-money valuation is computed as pre-money plus amount raised and is shown once the round closes — it is not a traded price. Financial statements are as reported by the issuer. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.